Geng JX, Lu YF, Zhou JN, Huang B, Qin Y. Exosome technology: A novel and effective drug delivery system in the field of cancer therapy. World J Gastrointest Oncol 2025; 17(3): 101857 [DOI: 10.4251/wjgo.v17.i3.101857]
Corresponding Author of This Article
Yuan Qin, PhD, Associate Professor, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 928 Second Avenue, Qiantang District, Hangzhou 310018, Zhejiang Province, China. qinyuan@zstu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jia-Xin Geng, Yao-Fan Lu, Biao Huang, Yuan Qin, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China
Jing-Nan Zhou, Zhejiang Cancer Hospital, Hangzhou 310018, Zhejiang Province, China
Author contributions: Qin Y designed this study; Geng JX, Lu YF, Zhou JN and Huang B performed the reference analyses; while Geng JX wrote the initial draft of the paper, with contributions from all authors.
Supported by Natural Science Foundation of Zhejiang Province, No. LQ23H050005; Zhejiang Medical and Health Science and Technology Project, No. 2023KY615; Scientific Research Project of Zhejiang Provincial Education Department, No. Y202250731 and No. Y202353130; the China Students’ Innovation and Entrepreneurship Training Program, No. 202310338044; China Postdoctoral Science Foundation, No. 2022M721720.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yuan Qin, PhD, Associate Professor, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 928 Second Avenue, Qiantang District, Hangzhou 310018, Zhejiang Province, China. qinyuan@zstu.edu.cn
Received: September 28, 2024 Revised: November 23, 2024 Accepted: December 20, 2024 Published online: March 15, 2025 Processing time: 138 Days and 19.1 Hours
Abstract
In this article, we revisit an article, which specifically focuses on the utilization of exosomes derived from human bone marrow mesenchymal stem cells (MSCs) for targeted delivery of gemcitabine in pancreatic cancer treatment. The experimental results demonstrated that the exosome-based drug delivery system derived from MSCs significantly augmented apoptosis in pancreatic cancer cells. The biocompatibility, targeting specificity, and low immunogenicity of exosomes render them as optimal carriers for drug delivery, enabling precise administration of therapeutics to diseased tissues while mitigating adverse effects, thereby achieving targeted treatment of cancer cells and significantly enhancing anti-tumor efficacy. However, the clinical application of exosome drug delivery platforms in oncology still presents challenges, necessitating further optimization to ensure their stability and efficacy. This study focuses on elucidating the advantages of exosomes as a drug delivery platform, exploring the utilization of MSC-derived exosomes in oncology therapy, and discussing their potential and future directions in cancer treatment.
Core Tip: The biocompatibility, targeting specificity, and low immunogenicity of exosomes render them as optimal carriers for drug delivery, enabling precise administration of therapeutics to diseased tissues, thereby achieving targeted treatment of cancer cells. However, the clinical application of exosome drug delivery platforms in oncology still presents challenges, necessitating further optimization to ensure their stability and efficacy. This study focuses on elucidating the advantages of exosomes as a drug delivery platform, exploring the utilization of mesenchymal stem cell-derived exosomes in oncology therapy, and discussing their potential and future directions in cancer treatment.
